2007 JASN IMPACT FACTOR 7.111	HOME   AUTHOR INFO   EDITORIAL BOARD   SUBSCRIBE   FEEDBACK   ALERTS   HELP
advanced	CURRENT ISSUE	ARCHIVES	JASN Express	ONLINE SUBMISSION

This Article Full Text Full Text (PDF) All Versions of this Article: ASN.2005040439v1 16/11/3437    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Wu, C. Articles by Unruh, M. Search for Related Content PubMed PubMed Citation Articles by Wu, C. Articles by Unruh, M.

Comorbid Conditions in Kidney Transplantation: Association with Graft and Patient Survival

Christine Wu^*, Idris Evans^*, Raymond Joseph^*, Ron Shapiro, Henkie Tan, Amit Basu, Cynthia Smetanka, Ahktar Khan, Jerry McCauley^*, and Mark Unruh^*

^* Department of Medicine, Renal-Electrolyte Division; and Department of Surgery, Starzl Transplantation Institute, University of Pittsburgh, Pittsburgh, Pennsylvania

Address correspondence to: Dr. Christine Wu, Department of Medicine, University of Pittsburgh, A915 Scaife Hall, 3550 Terrace Street, Pittsburgh, PA 15261. Phone: 412-647-7157; Fax: 412-647-6222; wucm{at}msx.upmc.edu

Received for publication April 27, 2005. Accepted for publication August 1, 2005.

Although the impact of comorbidity on outcomes in ESRD has been evaluated extensively, its contribution after kidney transplantation has not been well studied. It is believed that comorbidity assessment is critical to the informed interpretation of kidney transplant outcomes. In this study, the Charlson Comorbidity Index was used to assess the comorbid conditions of 715 patients who underwent kidney transplantation at the Starzl Transplant Institute between January 1998 and January 2003. The impact of pretransplantation comorbidity on the development of acute cellular rejection after transplantation and on patient and graft survival was examined. The most common comorbid conditions among our patient population were diabetes (n = 217, 30.3%) and heart failure (n = 85, 11.9%). It was found the number of patients with high comorbidity at the Starzl Transplant Institute has increased significantly over time (P = 0.04). In multivariate adjusted models, high comorbidity was associated with an increased risk for patient death, both in the perioperative period (hazard ratio 3.20, 95% confidence interval 1.32 to 7.78; P = 0.01) and >3 mo after transplantation (hazard ratio 2.63; 95% confidence interval 1.62 to 4.28; P < 0.001). The Charlson Comorbidity Index is a practical tool for the evaluation of comorbidity in the transplant population, which has an increasing burden of comorbid disease. Increased comorbidity affects both perioperative and long-term patient outcomes and carries significant implications not only for the development of individual patient therapeutic strategies but also for the interpretation of patient trials and the development of policies that govern distribution of donor organs.

This article has been cited by other articles:

				J. Moore, K. Tan, P. Cockwell, H. Krishnan, D. McPake, A. Ready, S. Mellor, A. Hamsho, S. Ball, G. Lipkin, et al. Predicting early renal allograft function using clinical variables Nephrol. Dial. Transplant., September 1, 2007; 22(9): 2669 - 2677. [Abstract] [Full Text] [PDF]

Copyright © 2008 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673